ArticleLung India : official organ of Indian Chest Society2026
The precision bronchodilator therapy in airflow limitation with asthma defining reversibility: An appraisal through pharmaco-responsiveness-based real-world observation.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe advent of glycopyrronium responsiveness (GPR) has opened an avenue for precision bronchodilator therapy in asthmatics.
methodsWe noted 2-Chair test (2CT) and spirometry with salbutamol bronchodilator-responsiveness (BDR) followed immediately by GPR in a cohort of asthmatics in an open, randomised observation. We treated (GINA stage-2 and 3) asthmatics with long-acting β2-agonist plus inhaled-corticosteroid (LABA-ICS) for salbutamol-BDR and with inhaled triple therapy (LABA-LAMA-ICS) for those having BDR and GPR. We compared the spirometry and 2-chair tests statistically between the initial and the follow-up status.
resultsThe two groups (30 each) were similar in demographic (age, body mass index), spirometric, and 2CT parameters. Post treatment (346.2 ± 242.3 and 390.2 ± 212.6 days for BDR and BDR+GPR-positive cases), both the groups improved universally. The GPR-positive triple drug treated group had similar change (215.7 ± 346.1 vs. 161.3 ± 318.7, P = 0.1578) in trough FEV1 but had a significantly higher value for post-salbutamol (449.0 ± 209.0 vs. 348.7 ± 282.2; P = 0.0201) and post-GP (531.7 ± 248.7 vs. 348.7 ± 282.2; P = 0.0015) FEV1 values on follow-up. The patients accepted the triple therapy universally without any serious adverse events. The two groups had similar number of mild exacerbations.
conclusionsThe pharmaco-responsiveness based add-on LAMA is seen to improve lung function of asthma in early GINA stages with parallel, though not significant, changes in the post-exercise recovery response (Desat-max in 2CT). The observation demands attention to consider upfront prescription of LAMA based on universal performance of GP responsiveness in asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.